ArticleEpidemiology (Cambridge, Mass.)2014
Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations.
Article in Epidemiology (Cambridge, Mass.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serum glucose and risk of cancer: a meta-analysis.BMC cancer · 2014Pooled it
- Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.Cancer prevention research (Philadelphia, Pa.) · 2017Trial
- Elderly Men with De Novo Metastatic Castration-Sensitive Prostate Cancer: Therapy and Does Comorbidity Matter.Medicina (Kaunas, Lithuania) · 2025Article
- Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study.Scientific reports · 2025Article
- Association of the dietary index for gut microbiota and dietary inflammation index with metabolic dysfunction-associated steatotic liver disease and metabolic alcohol-associated liver disease.Frontiers in immunology · 2025Article
- Associations of healthy eating index 2020 and its components with non-alcoholic fatty liver disease in type 2 diabetes patients and the mediating roles of metabolic indicators: NHANES 2007-2018.Frontiers in nutrition · 2025Article
- How competing risks affect the epidemiological relationship between vitamin D and prostate cancer incidence? A population-based study.Andrologia · 2022Article
- The Association of Excess Body Weight with Risk of ESKD Is Mediated Through Insulin Resistance, Hypertension, and Hyperuricemia.Journal of the American Society of Nephrology : JASN · 2022Article
- Different effect of obesity and metabolic syndrome on prostate cancer by age group.American journal of cancer research · 2022Article
- Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study.BMC medicine · 2020Article
- Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitus.International journal of cancer · 2018Article
- Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome.Hormones & cancer · 2018Article
- Associations between prediagnostic blood glucose levels, diabetes, and glioma.Scientific reports · 2017Article
- Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?Nature reviews. Clinical oncology · 2017Review
- Article
- Association between prediagnostic glucose, triglycerides, cholesterol and meningioma, and reverse causality.British journal of cancer · 2016Article
- Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer.Hormones & cancer · 2016Review
- Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Article
- CHADS2 scores as a predictor of ischemic stroke after radical prostatectomy.Cancer medicine · 2016Article
- Concomitant Gleason Score ≥ 7 prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy.International urology and nephrology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew previous studies of metabolic aberrations and prostate cancer risk have taken into account the fact that men with metabolic aberrations have an increased risk of death from causes other than prostate cancer. The aim of this study was to calculate, in a real-life scenario, the risk of prostate cancer diagnosis, prostate cancer death, and death from other causes.
methodsIn the Metabolic Syndrome and Cancer Project, prospective data on body mass index, blood pressure, glucose, cholesterol, and triglycerides were collected from 285,040 men. Risks of prostate cancer diagnosis, prostate cancer death, and death from other causes were calculated by use of competing risk analysis for men with normal (bottom 84%) and high (top 16%) levels of each factor, and a composite score.
resultsDuring a mean follow-up period of 12 years, 5,893 men were diagnosed with prostate cancer, 1,013 died of prostate cancer, and 26,328 died of other causes. After 1996, when prostate-specific antigen testing was introduced, men up to age 80 years with normal metabolic levels had 13% risk of prostate cancer, 2% risk of prostate cancer death, and 30% risk of death from other causes, whereas men with metabolic aberrations had corresponding risks of 11%, 2%, and 44%.
conclusionsIn contrast to recent studies using conventional survival analysis, in a real-world scenario taking risk of competing events into account, men with metabolic aberrations had lower risk of prostate cancer diagnosis, similar risk of prostate cancer death, and substantially higher risk of death from other causes compared with men who had normal metabolic levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.